Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Non-Current Liabilities: 2016-2024

Historic Other Non-Current Liabilities for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $1.1 million.

  • Rocket Pharmaceuticals' Other Non-Current Liabilities fell 7.09% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 7.09%. This contributed to the annual value of $1.1 million for FY2024, which is 61.14% down from last year.
  • Rocket Pharmaceuticals' Other Non-Current Liabilities amounted to $1.1 million in FY2024, which was down 61.14% from $2.9 million recorded in FY2023.
  • Rocket Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $2.9 million during FY2023, with a 5-year trough of $80,000 in FY2021.
  • Its 3-year average for Other Non-Current Liabilities is $2.2 million, with a median of $2.6 million in 2022.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first surged by 3,143.75% in 2022, then tumbled by 61.14% in 2024.
  • Over the past 5 years, Rocket Pharmaceuticals' Other Non-Current Liabilities (Yearly) stood at $136,000 in 2020, then plummeted by 41.18% to $80,000 in 2021, then surged by 3,143.75% to $2.6 million in 2022, then rose by 13.14% to $2.9 million in 2023, then plummeted by 61.14% to $1.1 million in 2024.